DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Lymphoma
Neuroblastoma
Retinoblastoma
Sarcoma
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: becatecarin

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200

Registration Number: NCT00006102

Locations: 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
Children's Healthcare of Atlanta - Scottish Rite, Atlanta, Georgia, United States
🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

and more 222 locations

Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 125

Registration Number: NCT00003745

Locations: 🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 231 locations

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Phase 2

Completed

Conditions: Metastatic Osteosarcoma

Interventions: Drug: doxorubicin hydrochloride
Drug: cisplatin
Drug: methotrexate
Drug: leucovorin calcium
Biological: filgrastim
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Drug: etoposide
Drug: ifosfamide
Biological: trastuzumab
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00023998

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: cisplatin
Radiation: radiation therapy
Drug: etoposide
Drug: paclitaxel
Drug: carboplatin
Drug: docetaxel
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00042835

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer

Phase 1

Terminated

Conditions: Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer

Interventions: Drug: fluorouracil
Drug: sodium phenylbutyrate
Drug: indomethacin
Biological: recombinant interferon gamma

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00002796

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Not Applicable

Terminated

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Prolymphocytic Leukemia
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Splenic Marginal Zone Lymphoma

Interventions: Drug: arsenic trioxide
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00005786

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Male Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: becatecarin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00005817

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Bone Metastases
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: rebimastat
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 68

Registration Number: NCT00040755

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Phase 1

Terminated

Conditions: HER2-positive Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Biological: trastuzumab
Drug: alvocidib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00039455

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00016094

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy